THE TROPONIN PROGNOSTIC CAPABILITY IN DIAGNOSING CARDIOTOXICITY DURING CHEMOTHERAPY WITH ANTHRACYCLINES AND MONOCLONAL ANTIBODIES IN BREAST CANCER PATIENTS
Introduction. Breast cancer is sensitive to some schemes of chemotherapy known to be aggressive towards the cardiovascular system. There is anthracycline-mediated irreversible cardiotoxicity of the first type and trastuzumab-mediated reversible cardiotoxicity of the second type. The use of serum biomarkers capable of detecting myocardial injury before symptoms appear is an alternative approach to early diagnosis of the chemotherapy cardiotoxic complications.
Aim: analyze the prognostic value of troponin for the early detection of cardiotoxic complications caused by anthracycline and/or trastuzumab in breast cancer patients.
Search strategy: The search was carried out across the databases Pubmed, Web of Science, Scopus, e-LIBRARY. Criteria for inclusion in the review were: randomized controlled trials and prospective studies dated 2010–2020. The keywords were used according to the following sections: pathology: "breast cancer", "breast"; treatment: «anthracyclines», «trastuzumab», «chemotherapy»; biomarkers: «troponin», «troponin I», «troponin T», «high sensitive troponin»; complications of chemotherapy: "cardiotoxicity", studies: "controlled trial", "randomized controlled trial", "controlled clinical trial", "clinical trial". The selection of studies was carried out by the triangulation method. In total, the review included full-text 27 studies that completely met the search criteria. The list of references also contains researches that did not meet the search criteria, but illustrating the relevance of the topic.
Results. An increase in troponin levels may signify the development of cardiac dysfunction with a poor prognosis, especially if troponin levels continue to rise. The increase in the hs-troponin and the integral of the increase are more reliable predictors than the absolute value of troponin.
Сonclusions. Breast cancer patients receiving anthracyclines and subsequent targeted chimiotherapy have the highest risk of cardiotoxic complications. Troponin level monitoring has predictive potential and should be considered to all patients receiving chemotherapy. Troponin and the combination of several markers may turn out to be more sensitive in predicting cardiotoxicity in patients treated with anthracyclines and trastuzumab.
Zhenisgul Sh. Tlegenova1, http://orcid.org/0000-0002-3707-7365
Bekolat K. Zholdin1, http://orcid.org/0000-0002-4245-9501
Gennadij E. Gendlin2, http://orcid.org/0000-0002-7846-1611
Saule K. Balmagambetova1, http://orcid.org/0000-0003-4080-5383
Gulnara L. Kurmanalina1, http://orcid.org/0000-0002-0937-2949
Iliada Zh. Talipova1, http://orcid.org/0000-0002-5450-7056
1 West Kazakhstan Marat Ospanov Medical University, Aktobe, Republic of Kazakhstan;
2 N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation.
1. Авалян А.А., Ощепкова Е.В., Саидова М.А., Шитов В.Н., Глазкова Е.В., Стенина М.Б., Чазова И.Е. Оценка субклинической кардиотоксичности антрациклинсодержащей химиотерапии рака молочной железы в зависимости от кумулятивной дозы доксорубицина и исходного уровня артериального давления // Системные гипертензии. 2018. №4. URL: https://cyberleninka.ru/article/n/otsenka-subklinicheskoy-kardiotoksichnosti-antratsiklinsoderzhaschey-himioterapii-raka-molochnoy-zhelezy-v-zavisimosti-ot (дата обращения: 30.05.2021).
2. Васюк Ю.А., Школьник Е.Л, Несветов В.В., Школьник Л.Д., Селезнева М.Г. Кардионкология: современные аспекты диагностики сердечно-сосудистых осложнений при противоопухолевой терапии // Cердечная недостаточность. 2016. 17(6). С. 383-387. doi: 10.18087/rhfj.2016.6.2327.
3. Гендлин Г.Е., Емелина Е.И., Никитин И.Г., Васюк Ю.А. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики // РКЖ. 2017. №3 (143). URL: https://cyberleninka.ru/article/n/sovremennyy-vzglyad-na-kardiotoksichnost-himioterapii-onkologicheskih-zabolevaniy-vklyuchayuschey-antratsiklinovye-antibiotiki (дата обращения: 21.05.2021).
4. Altena R., Perik P.J., van Veldhuisen D.J., de Vries E.G., Gietema J.A. Cardiovascular toxicity caused by cancer treatment: strategies for early detection // Lancet Oncol. 2009; 10(4). Р. 391-399. doi: 10.1016/S1470-2045(09)70042-7.
5. Ananthan K., Lyon A.R. The Role of Biomarkers in Cardio-Oncology // J Cardiovasc Transl Res. 2020. 13(3). Р. 431-450. doi: 10.1007/s12265-020-10042-3.
6. Apple F.S. A new season for cardiac troponin assays: it’s time to keep a scorecard // Clin Chem. 2009. 55 (7). P. 1303-1306. doi: 10.1373/clinchem.2009.128363.
7. Armenian S.H., Lacchetti C., Barac A., Carver J., Constine L.S., Denduluri N., Dent S., Douglas P.S., et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline // J Clin Oncol 2017. 35(8). P. 893–911. doi: 10.1200/JCO.2016.70.5400.
8. Avila M.S., Ayub-Ferreira S.M., de Barros Wanderley M.R. Jr., das Dores Cruz F., Gonçalves Brandão S.M., Rigaud V.O.C., Higuchi-Dos-Santos M.H., et al. Carvedilol for Prevention of Chemotherapy-Related Cardiotoxicity: The CECCY Trial //J Am Coll Cardiol. 2018. 71(20). P. 2281-2290. doi: 10.1016/j.jacc.2018.02.049.
9. Ben Kridis W., Sghaier S., Charfeddine S., Toumi N., Daoud J., Kammoun S., Khanfir A. A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer // Am J Clin Oncol. 2020. 43(7). P. 510-516. doi: 10.1097/COC.0000000000000699.
10. Boekhout A.H., Gietema J.A., Milojkovic Kerklaan B., van Werkhoven E.D., Altena R., Honkoop A., Los M., Smit W.M., Nieboer P., Smorenburg C.H., et al. Angiotensin II-Receptor Inhibition With Candesartan to Prevent Trastuzumab-Related Cardiotoxic Effects in Patients With Early Breast Cancer: A Randomized Clinical Trial // JAMA Oncol. 2016. 2(8). P.1030-1037. doi: 10.1001/jamaoncol.2016.1726.
11. Bowles E.J., Wellman R., Feigelson H.S., Onitilo A.A., Freedman A.N., Delate T., Allen L.A., Nekhlyudov L., Goddard K.A., Davis R.L., et al. Pharmacovigilance Study Team. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study // J Natl Cancer Inst. 2012. 104(17). P. 1293-1305. doi: 10.1093/jnci/djs317.
12. Bracun V., Aboumsallem J.P., van der Meer P., de Boer R.A. Cardiac Biomarkers in Patients with Cancer: Considerations, Clinical Implications, and Future Avenues // Curr Oncol Rep. 2020. 22(7). 67. doi: 10.1007/s11912-020-00930-x.
13. Bray F., Ferlay J., Soerjomataram I., Siegel R.L., Torre L.A., Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries // CA Cancer J Clin. 2018. 68(6). P. 394-424. doi: 10.3322/caac.21492.
14. Cardinale D., Ciceri F., Latini R., Franzosi M.G., Sandri M.T., Civelli M., Cucchi G., Menatti E., Mangiavacchi M., Cavina R., et al. ICOS-ONE Study Investigators. Anthracycline-induced cardiotoxicity: A multicenter randomised trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial // Eur J Cancer. 2018. 94. P. 126-137. doi: 10.1016/j.ejca.2018.02.005.
15. Cardinale D., Colombo A., Bacchiani G., Tedeschi I., Meroni C.A., Veglia F., Civelli M., Lamantia G., Colombo N., Curigliano G., Fiorentini C., Cipolla C.M. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy // Circulation. 2015. 131(22). P. 1981-1988. doi: 10.1161/CIRCULATIONAHA.114.013777.
16. Cardinale D., Colombo A., Torrisi R., Sandri M.T., Civelli M., Salvatici M., Lamantia G., Colombo N., Cortinovis S., Dessanai M.A., Nolè F., Veglia F., Cipolla C.M. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation // J Clin Oncol. 2010. 28(25). P. 3910-3916. doi: 10.1200/JCO.2009.27.3615.
17. Colombo A, Cipolla C, Beggiato M, Cardinale D. Cardiac toxicity of anticancer agents // Curr Cardiol Rep. 2013. 15(5). 362. doi: 10.1007/s11886-013-0362-6.
18. Curigliano G., Lenihan D., Fradley M., Ganatra S., Barac A., Blaes A., Herrmann J., Porter C., Lyon A.R., Lancellotti P. et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations // Ann Oncol. 2020. 31(2). P. 171-190. doi: 10.1016/j.annonc.2019.10.023.
19. de Lemos J.A., Drazner M.H., Omland T., Ayers C.R., Khera A., Rohatgi A., Hashim I., Berry J.D., Das S.R., Morrow D.A., McGuire D.K. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population // JAMA. 2010. 304(22). P. 2503-12. doi: 10.1001/jama.2010.1768.
20. Demissei B.G., Hubbard R.A., Zhang L., Smith A.M., Sheline K., McDonald C., Narayan V., Domchek S.M., DeMichele A., Shah P., et al. Changes in Cardiovascular Biomarkers With Breast Cancer Therapy and Associations With Cardiac Dysfunction // J Am Heart Assoc. 2020. 9(2). e014708. doi: 10.1161/JAHA.119.014708.
21. Dhir V., Yan A.T., Nisenbaum R., Sloninko J., Connelly K.A., Barfett J., Haq R., Kirpalani A., Chan K.K.W., Petrella T.M., Brezden-Masley C. Assessment of left ventricular function by CMR versus MUGA scans in breast cancer patients receiving trastuzumab: a prospective observational study // Int J Cardiovasc Imaging. 2019. 35(11). P. 2085-2093. doi: 10.1007/s10554-019-01648-z.
22. Eggers K.M., Lindahl B., Melki D., Jernberg T. Consequences of implementing a cardiac troponin assay with improved sensitivity at Swedish coronary care units: an analysis fr om the SWEDEHEART registry // Eur Heart J. 2016. 37(30). P. 2417-24. doi: 10.1093/eurheartj/ehw029.
23. Ewer M.S., Ewer S.M. Cardiotoxicity of anticancer treatments // Nat Rev Cardiol. 2015. 12(9). P. 547-558. doi: 10.1038/nrcardio.2015.65.
24. Fallah-Rad N., Walker J.R., Wassef A., Lytwyn M., Bohonis S., Fang T., Tian G., Kirkpatrick I.D., Singal P.K., Krahn M., Grenier D., Jassal D.S. The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy // J Am Coll Cardiol. 2011. 57(22). P. 2263-70. doi: 10.1016/j.jacc.2010.11.063.
25. Farmakis D., Mueller C., Apple F.S. High-sensitivity cardiac troponin assays for cardiovascular risk stratification in the general population // Eur Heart J. 2020. 41(41). P. 4050-4056. doi: 10.1093/eurheartj/ehaa083.
26. Feola M., Garrone O., Occelli M., Francini A., Biggi A., Visconti G., Albrile F., Bobbio M., Merlano M. Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide // Int J Cardiol. 2011. 148(2). P. 194-198. doi: 10.1016/j.ijcard.2009.09.564.
27. Ferlay J., Colombet M., Soerjomataram I., Parkin D.M., Piñeros M., Znaor A., Bray F. Cancer statistics for the year 2020: An overview // Int J Cancer. 2021. Apr 5. doi: 10.1002/ijc.33588.
28. Gavila J., Seguí M.Á., Calvo L., López T., Alonso J.J., Farto M., Sánchez-de la Rosa R. Evaluation and management of chemotherapy-induced cardiotoxicity in breast cancer: a Delphi study // Clin Transl Oncol. 2017. 19(1). P. 91-104. doi: 10.1007/s12094-016-1508-y.
29. Gernaat S.A.M., Ho P.J., Rijnberg N., Emaus M.J., Baak L.M., Hartman M., Grobbee D.E., Verkooijen H.M. Risk of death fr om cardiovascular disease following breast cancer: a systematic review // Breast Cancer Res Treat. 2017. 164(3). P. 537-555. doi: 10.1007/s10549-017-4282-9.
30. Goel S., Liu J., Guo H., Barry W., Bell R., Murray B., Lynch .J, Bastick P., Chantrill L., Kiely B.E., Abdi E., et al. Decline in Left Ventricular Ejection Fraction Following Anthracyclines Predicts Trastuzumab Cardiotoxicity // JACC Heart Fail. 2019 .7(9). P. 795-804. doi: 10.1016/j.jchf.2019.04.014.
31. Gulati G., Heck S.L., Røsjø H., Ree A.H., Hoffmann P., Hagve T.A., Norseth J., Gravdehaug B., Steine K., Geisler J., Omland T. Neurohormonal Blockade and Circulating Cardiovascular Biomarkers During Anthracycline Therapy in Breast Cancer Patients: Results From the PRADA (Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy) Study // J Am Heart Assoc. 2017. 6(11). e006513. doi: 10.1161/JAHA.117.006513.
32. Hamo C.E., Bloom M.W., Cardinale D., Ky B., Nohria A., Baer L., Skopicki H., Lenihan D.J., Gheorghiade M., Lyon A.R., Butler J. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 2: Prevention, Treatment, Guidelines, and Future Directions // Circ Heart Fail. 2016. 9(2). e002843. doi: 10.1161/CIRCHEARTFAILURE.115.002843.
33. Jensen B.V., Skovsgaard T., Nielsen S.L. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients // Ann Oncol. 2002. 13(5). P. 699-709. doi: 10.1093/annonc/mdf132.
34. Kitayama H., Kondo T., Sugiyama J., Kurimoto K., Nishino Y., Kawada M., Hirayama M., Tsuji Y. High-sensitive troponin T assay can predict anthracycline- and trastuzumab-induced cardiotoxicity in breast cancer patients // Breast Cancer. 2017. 4(6). P. 774-782. doi: 10.1007/s12282-017-0778-8.
35. Ky B., Putt M., Sawaya H., French B., Januzzi J.L ., Sebag I.A., Plana J.C., Cohen V., Banchs J., Carver J.R., et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab // J Am Coll Cardiol. 2014. 63(8). P. 809-816. doi: 10.1016/j.jacc.2013.10.061.
36. Mahjoob M.P., Sheikholeslami S.A., Dadras M., Mansouri H., Haghi M., Naderian M., Sadeghi L., Tabary M., Khaheshi I. Prognostic Value of Cardiac Biomarkers Assessment in Combination with Myocardial 2D Strain Echocardiography for Early Detection of Anthracycline-Related Cardiac Toxicity.B // Cardiovasc Hematol Disord Drug Targets. 2020. 20(1). P. 74-83. doi: 10.2174/1871529X19666190912150942.
37. Mantarro S., Rossi M., Bonifazi M., D'Amico R., Blandizzi C., La Vecchia C., Negri E., Moja L. Risk of severe cardiotoxicity following treatment with trastuzumab: a meta-analysis of randomized and cohort studies of 29,000 women with breast cancer // Intern Emerg Med. 2016. 11(1). P. 123-40. doi: 10.1007/s11739-015-1362-x.
38. McArthur H.L., Rugo H., Nulsen B., Hawks L., Grothusen J., Melisko M., Moasser M., Paulson M., Traina T., Patil S., Zhou Q., Steingart R., et al. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer // Clin Cancer Res. 201. 17(10). P. 3398-3407. doi: 10.1158/1078-0432.CCR-10-1969.
39. McGowan J.V., Chung R., Maulik A., Piotrowska I., Walker J.M., Yellon D.M. Anthracycline chemotherapy and cardiotoxicity // Cardiovascular Drugs and Therapy. 2017. 31(1). P. 63–75. doi: 10.1007/s10557-016-6711-0.
40. Michel L., Mincu R.I., Mahabadi A.A., Settelmeier S., Al-Rashid F., Rassaf T., Totzeck M. Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: a meta-analysis // Eur J Heart Fail. 2020. 22(2). P. 350-361. doi: 10.1002/ejhf.1631.
41. Morris P.G., Chen C., Steingart R., Fleisher M., Lin N., Moy B., Come S., Sugarman S., Abbruzzi A., Lehman R., et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemotherapy incorporating trastuzumab and lapatinib // Clin Cancer Res. 2011. 17(10). P. 3490-3499. doi: 10.1158/1078-0432.CCR-10-1359.
42. Moslehi J.J. Cardiovascular toxic effects of targeted cancer therapies // The New England Journal of Medicine. 2016. 375(15). P. 1457–1467. doi: 10.1056/NEJMra1100265.
43. O'Brien P.J. Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity // Toxicology. 2008. 245(3). P. 206-18. doi: 10.1016/j.tox.2007.12.006.
44. Oikonomou E.K., Kokkinidis D.G., Kampaktsis P.N., Amir E.A., Marwick T.H., Gupta D., Thavendiranathan P. Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis // JAMA Cardiol. 2019. 4(10). P. 1007-1018. doi: 10.1001/jamacardio.2019.2952.
45. Patnaik J.L., Byers T., DiGuiseppi C., Dabelea D., Denberg T.D. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study // Breast Cancer Res. 2011. 13(3). R64. doi: 10.1186/bcr2901.
46. Plana J.C., Galderisi M., Barac A., Ewer M.S., Ky B., Scherrer-Crosbie M., Ganame J., Sebag I.A., Agler D.A., Badano L.P., et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging // Eur Heart J Cardiovasc Imaging. 2014. 15(10). P. 1063-1093. doi: 10.1093/ehjci/jeu192.
47. Ponde N., Bradbury I., Lambertini M., Ewer M., Campbell C., Ameels H., Zardavas D., Di Cosimo S., Baselga J., Huober J., et al. Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06) // Breast Cancer Res Treat. 2018. 168(3). P. 631-638. doi: 10.1007/s10549-017-4628-3.
48. Putt M., Hahn V.S., Januzzi J.L., Sawaya H., Sebag I.A., Plana J.C., Picard M.H., Carver J.R., Halpern E.F., Kuter I., et al. Longitudinal Changes in Multiple Biomarkers Are Associated with Cardiotoxicity in Breast Cancer Patients Treated with Doxorubicin, Taxanes, and Trastuzumab // Clin Chem. 2015. 61(9). P. 1164-1172. doi: 10.1373/clinchem.2015.241232.
49. Reagan W.J. Troponin as a biomarker of cardiac toxicity: past, present, and future // Toxicol Pathol. 2010. 38(7). P. 1134-1137. doi: 10.1177/0192623310382438.
50. Rüger A.M., Schneeweiss A., Seiler S., Tesch H., van Mackelenbergh M., Marmé F., Lübbe K., Sinn B., Karn T., Stickeler E., et al. Cardiotoxicity and Cardiovascular Biomarkers in Patients With Breast Cancer: Data From the Gepar Octo-GBG 84 Trial // J Am Heart Assoc. 2020. 9(23). e018143. doi: 10.1161/JAHA.120.018143.
51. Saunders J.T., Nambi V., de Lemos J.A., Chambless L.E., Virani S.S., Boerwinkle E., Hoogeveen R.C., Liu X., Astor B.C., Mosley T.H., et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study // Circulation. 2011. 123(13).P. 1367-1376. doi: 10.1161/CIRCULATIONAHA.110.005264.
52. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Cohen V., Gosavi S., Carver J.R., Wiegers S.E., Martin R.P., Picard M.H., et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients // Am J Cardiol. 2011. 107(9). P. 1375-1380. doi: 10.1016/j.amjcard.2011.01.006.
53. Sawaya H., Sebag I.A., Plana J.C., Januzzi J.L., Ky B., Tan T.C., Cohen V., Banchs J., Carver J.R., Wiegers S.E., et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab // Circ Cardiovasc Imaging. 2012. 5(5). P. 596-603. doi: 10.1161/CIRCIMAGING.112.973321.
54. Schwartz R.G., Jain D., Storozynsky E. Traditional and novel methods to assess and prevent chemotherapy-related cardiac dysfunction noninvasively // J Nucl Cardiol. 2013. 20(3). P. 443–464. doi: 10.1007/s12350-013-9707-1.
55. Shafi A., Siddiqui N., Imtiaz S., Din Sajid M.U. Left Ventricular Systolic Dysfunction Predicted By Early Troponin I Release After Anthracycline Based Chemotherapy In Breast Cancer Patients // J Ayub Med Coll Abbottabad. 2017. 29(2). P. 266-269.
56. Slamon D., Eiermann W., Robert N., Pienkowski T., Martin M., Press M., Mackey J., Glaspy J., Chan A., Pawlicki M., et al. Breast Cancer International Research Group. Adjuvant trastuzumab in HER2-positive breast cancer // N Engl J Med. 2011. 365(14). P. 1273-83. doi: 10.1056/NEJMoa0910383.
57. Słowik A., Jagielski P., Potocki P., Streb J., Ochenduszko S., Wysocki P., Gajos G., Konduracka E. Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study // Kardiol Pol. 2020. 78(2). P. 131-137. doi: 10.33963/KP.15163.
58. Steingart R.M., Chandrashekhar Y., Marwick T.H. Imaging in Cardio-Oncology: Wh ere Are We and Wh ere Should We Be Going? // JACC Cardiovasc Imaging. 2018. 11(8). P. 1209-1211. doi: 10.1016/j.jcmg.2018.07.001.
59. Suter T.M., Ewer M.S. Cancer drugs and the heart: importance and management // Eur Heart J. 2013. 34(15). P. 1102-11. doi: 10.1093/eurheartj/ehs181.
60. Swain S.M., Whaley F.S., Ewer M.S. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials // Cancer. 2003. 97(11). P. 2869-2879. doi: 10.1002/cncr.11407.
61. Tzolos E., Adamson P.D., Hall P.S., Macpherson I.R., Oikonomidou O., MacLean M., Lewis S.C., McVicars H., Newby D.E., Mills N.L., Lang N.N., Henriksen P.A. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy // Clin Oncol (R Coll Radiol). 2020. 32(5). P. 292-297. doi: 10.1016/j.clon.2019.11.008.
62. van Boxtel W., Bulten B.F., Mavinkurve-Groothuis A.M., Bellersen L., Mandigers C.M., Joosten L.A., Kapusta L., de Geus-Oei L.F., van Laarhoven H.W. New biomarkers for early detection of cardiotoxicity after treatment with docetaxel, doxorubicin and cyclophosphamide // Biomarkers. 2015. 20(2). P. 143-148. doi: 10.3109/1354750X.2015.1040839.
63. Yu A.F., Manrique C., Pun S., Liu J.E., Mara E., Fleisher M., Patil S., Jones L.W., Steingart R.M., Hudis C.A., Dang C.T. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer // Oncologist. 2016. 21(4). P. 418-424. doi: 10.1634/theoncologist.2015-0321.
64. Welsh P., Preiss D., Hayward C., Shah A.S.V., McAllister D., Briggs A., Boachie C., McConnachie A., Padmanabhan S., Welsh C., Woodward M., Campbell A., Porteous D., Mills N.L., Sattar N. Cardiac Troponin T and Troponin I in the General Population // Circulation. 2019. 139(24). P. 2754-2764. doi: 10.1161/CIRCULATIONAHA.118.038529.
65. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R, et al. Authors/Task Force Members; ESC Committee for Practice Guidelines (CPG); Document Reviewers. 2016. ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) // Eur J Heart Fail. 2017. 19(1). P. 9-42. doi: 10.1002/ejhf.654.
66. Zardavas D., Suter T.M., Van Veldhuisen D.J., Steinseifer J., Noe J., Lauer S., Al-Sakaff N., Piccart-Gebhart M.J., de Azambuja E. Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant Study Cardiac Marker Substudy // J Clin Oncol. 2017. 35(8). P. 878-884. doi: 10.1200/JCO.2015.65.7916.
References [1-3]:
1. Avalyan A. A., Oshchepkova E. V., Saidova M. A., Shitov V. N., Glazkova E. V., Stenina M. B., Chazova I. E. Otsenka subklinicheskoy kardiotoksichnosti antratsiklin soderzhashchey khimioterapii raka molochnoy zhelezy v zavisimosti ot kumulyativnoy dozy doksorubitsina i iskhodnogo urovnya arterial'nogo davleniya [Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy]. Sistemnye gipertenzii [Systemic Hypertension]. 2018. №4. URL: https://cyberleninka.ru/article/n/otsenka-subklinicheskoy-kardiotoksichnosti-antratsiklinsoderzhaschey-himioterapii-raka-molochnoy-zhelezy-v-zavisimosti-ot (data obrashcheniya: 30.05.2021). [in Russian]
2. Vasyuk Yu.A., Shkol'nik E.L, Nesvetov V.V., Shkol'nik L.D., Selezneva M.G. Kardionkologiya: sovremennye aspekty diagnostiki serdechno-sosudistykh oslozhneniy pri protivoopukholevoy terapii [Cardio-oncology: current aspects in diagnocs for cardiovascular complications of antitumor therapy]. Serdechnaya nedostatochnost' [Heart Failurel]. 2016. 17(6). pp. 383-387. doi: 10.18087/rhfj.2016.6.2327. [in Russian]
3. Gendlin G.E., Emelina E.I., Nikitin I.G., Vasyuk Yu.A. Sovremennyy vzglyad na kardiotoksichnost' khimioterapii onkologicheskikh zabolevaniy, vklyuchayushchey antratsiklinovye antibiotiki [Modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines]. RKZh [Russ J Cardiol]. 2017. №3.(143). pp. 145-154. doi: 10.15829/1560-4071-2017-3-145-154. [in Russian]
Number of Views: 190
Category of articles:
Reviews
Bibliography link
Tlegenova Zh.Sh., Zholdin B.K., Gendlin G.E., Balmagambetova S.K., Kurmanalina G.L., Talipova I.Zh. The Troponin prognostic capability in diagnosing cardiotoxicity during chemotherapy with anthracyclines and monoclonal antibodies in breast cancer patients // Nauka i Zdravookhranenie [Science & Healthcare]. 2021, (Vol.23) 5, pp. 132-148. doi 10.34689/SH.2021.23.5.016Related publications:
INTERRELATION OF INTRAABDOMINAL HYPERTENSION AND MARKERS OF GASTROINTESTINAL TRACT INJURY IN PATIENTS WITH MULTIORGAN DYSFUNCTION
DRUG-INDUCED LIVER INJURY AND GENDER DIFFERENCES
QUALITY OF LIFE IN PRIMARY BILIARY CHOLANGITIS AND ITS ASSESSMENT
DIAGNOSTIC AND THERAPEUTIC LAPAROSCOPY FOR ABDOMINAL INJURIES. REVIEW
METHODS FOR SCHOOL-AGE CHILDREN NUTRITIONAL STATUS ASSESSMENT: FOCUS ON ANTHROPOMETRIC PARAMETERS. A REVIEW.